Recent executive action has accelerated federal marijuana rescheduling under the Controlled Substances Act. A December 2025 presidential executive order directed the Justice Department and DEA to complete rulemaking moving marijuana from Schedule I to Schedule III as quickly as possible under federal law. In April 2026, the acting attorney general issued a final order that immediately transferred FDA-approved marijuana products and state-licensed medical marijuana to Schedule III, effective late April, while restarting an expedited administrative process for broader rescheduling. An expedited DEA hearing on the full proposal ran from June 29 to July 15, 2026, after earlier proceedings were withdrawn to speed review. Post-hearing briefs are due by mid-August 2026, with an administrative law judge recommendation and DEA final rule expected to follow, subject to potential appeals or further comment periods. Traders weigh these remaining procedural milestones against the compressed timeline established by the executive order when assessing completion dates.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено$791,969 Обс.
Mar 31, 2026
September 30
14%
December 31
28%
$791,969 Обс.
September 30
$0 Обс.
14%
December 31
$182,399 Обс.
28%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent executive action has accelerated federal marijuana rescheduling under the Controlled Substances Act. A December 2025 presidential executive order directed the Justice Department and DEA to complete rulemaking moving marijuana from Schedule I to Schedule III as quickly as possible under federal law. In April 2026, the acting attorney general issued a final order that immediately transferred FDA-approved marijuana products and state-licensed medical marijuana to Schedule III, effective late April, while restarting an expedited administrative process for broader rescheduling.
An expedited DEA hearing on the full proposal ran from June 29 to July 15, 2026, after earlier proceedings were withdrawn to speed review. Post-hearing briefs are due by mid-August 2026, with an administrative law judge recommendation and DEA final rule expected to follow, subject to potential appeals or further comment periods. Traders weigh these remaining procedural milestones against the compressed timeline established by the executive order when assessing completion dates.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Ринок відкрито: Feb 7, 2026, 5:04 PM ET
Обсяг
$791,969Дата завершення
Mar 31, 2026Ринок відкрито
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent executive action has accelerated federal marijuana rescheduling under the Controlled Substances Act. A December 2025 presidential executive order directed the Justice Department and DEA to complete rulemaking moving marijuana from Schedule I to Schedule III as quickly as possible under federal law. In April 2026, the acting attorney general issued a final order that immediately transferred FDA-approved marijuana products and state-licensed medical marijuana to Schedule III, effective late April, while restarting an expedited administrative process for broader rescheduling.
An expedited DEA hearing on the full proposal ran from June 29 to July 15, 2026, after earlier proceedings were withdrawn to speed review. Post-hearing briefs are due by mid-August 2026, with an administrative law judge recommendation and DEA final rule expected to follow, subject to potential appeals or further comment periods. Traders weigh these remaining procedural milestones against the compressed timeline established by the executive order when assessing completion dates.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Обсяг
$791,969Дата завершення
Mar 31, 2026Ринок відкрито
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent executive action has accelerated federal marijuana rescheduling under the Controlled Substances Act. A December 2025 presidential executive order directed the Justice Department and DEA to complete rulemaking moving marijuana from Schedule I to Schedule III as quickly as possible under federal law. In April 2026, the acting attorney general issued a final order that immediately transferred FDA-approved marijuana products and state-licensed medical marijuana to Schedule III, effective late April, while restarting an expedited administrative process for broader rescheduling. An expedited DEA hearing on the full proposal ran from June 29 to July 15, 2026, after earlier proceedings were withdrawn to speed review. Post-hearing briefs are due by mid-August 2026, with an administrative law judge recommendation and DEA final rule expected to follow, subject to potential appeals or further comment periods. Traders weigh these remaining procedural milestones against the compressed timeline established by the executive order when assessing completion dates.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання